Please enable JavaScript to continue using this application.

Compare $CAMP vs $KROS | Chartloom

Compare

$CAMP vs $KROS

CAMP4 Therapeutics Corp · Keros Therapeutics Inc

CAMP

CAMP4 Therapeutics Corp

KROS

Keros Therapeutics Inc

Compare $CAMP vs $KROS

Comparing CAMP4 Therapeutics Corp and Keros Therapeutics Inc

CAMPCAMP4 Therapeutics Corp

KROSKeros Therapeutics Inc

CAMPCAMP4 Therapeutics Corp

Market cap

$196M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

19.59x

Rev growth (TTM)

40.3%

YTD performance

-37.2%

52W performance

6.5%

FCF yield

-14.7%

KROSKeros Therapeutics Inc

Market cap

$236M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-93.6%

YTD performance

-35.5%

52W performance

-25.1%

FCF yield

-20.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CAMP

KROS

Detailed metrics comparison

CAMP

CAMP4 Therapeutics Corp

KROS

Keros Therapeutics Inc

Market Cap

CAMP$196M

KROS$236M

Enterprise Value

CAMP$109M

KROS$-21M

Price

CAMP$3.77

KROS$11.95

P/E Ratio

CAMPN/A

KROSN/A

P/S Ratio

CAMP46.44x

KROS15.75x

EV/Sales

CAMP25.94x

KROS-1.41x

EV/EBITDA

CAMP0.00x

KROS-0.47x

P/B Ratio

CAMP8.12x

KROS0.86x

P/FCF Ratio

CAMPN/A

KROSN/A

EV/FCF

CAMP-3.81x

KROS0.44x

PEG Ratio

CAMPN/A

KROSN/A

Forward P/E (NTM)

CAMPN/A

KROSN/A

Forward P/S (NTM)

CAMP19.59x

KROSN/A

Revenue (TTM)

CAMP$4M

KROS$15M

Revenue Growth (YoY)

CAMP40.3%

KROS-93.6%

Forward Rev Growth

CAMP-10.8%

KROS-96.3%

Gross Margin (TTM)

CAMP35.8%

KROS0.0%

Operating Margin (TTM)

CAMP0.0%

KROS0.0%

EBITDA Margin (TTM)

CAMP-1199.3%

KROS-665.2%

Net Margin (TTM)

CAMP-2543.7%

KROS-553.9%

FCF Margin (TTM)

CAMP-681.2%

KROS-322.9%

Net Income (TTM)

CAMP$-107M

KROS$-83M

FCF (TTM)

CAMP$-29M

KROS$-48M

EPS (TTM)

CAMP-$1.85

KROS-$4.20

ROE (TTM)

CAMP-19474.0%

KROS-2140.0%

ROA (TTM)

CAMP-10642.0%

KROS-1979.0%

ROIC (TTM)

CAMP-19457.0%

KROS-2140.0%

Cash

CAMP$86M

KROS$258M

Debt

CAMP$0

KROS$0

Net Cash/Debt

CAMP$86M

KROS$258M

Current Ratio (TTM)

CAMP4.70x

KROS21.96x

Quick Ratio (TTM)

CAMP4.69x

KROS21.53x

Debt/Equity (TTM)

CAMP0.00x

KROS0.00x

Debt/Assets (TTM)

CAMP0.0%

KROS0.0%

Interest Coverage (TTM)

CAMPN/A

KROSN/A

Net Debt/EBITDA (TTM)

CAMP0.00x

KROS0.00x

Beta

CAMP-24.51

KROS1.20

52W Performance

CAMP6.5%

KROS-25.1%

YTD Performance

CAMP-37.2%

KROS-35.5%

% from 52W High

CAMP-51.4%

KROS-47.0%

% from 52W Low

CAMP31.8%

KROS23.3%

Asset Turnover (TTM)

CAMP0.79x

KROS0.06x

FCF Yield (TTM)

CAMP-14.7%

KROS-20.5%

Earnings Yield (TTM)

CAMP-54.8%

KROS-35.2%

Dividend Yield (TTM)

CAMPN/A

KROSN/A

Rule of 40

CAMP-640.9

KROS-416.5

EV/GP/RG

CAMP0.53

KROSN/A

Ticker research

View CAMP research View KROS research

Metric	CAMP CAMP4 Therapeutics Corp	KROS Keros Therapeutics Inc
Market & Valuation
Market Cap	$196M	$236M
Enterprise Value	$109M	$-21M
Price	$3.77	$11.95
P/E Ratio	N/A	N/A
P/S Ratio	46.44x	15.75x
EV/Sales	25.94x	-1.41x
EV/EBITDA	0.00x	-0.47x
P/B Ratio	8.12x	0.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.81x	0.44x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	19.59x	N/A
Revenue & Growth
Revenue (TTM)	$4M	$15M
Revenue Growth (YoY)	40.3%	-93.6%
Forward Rev Growth	-10.8%	-96.3%
Profitability
Gross Margin (TTM)	35.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1199.3%	-665.2%
Net Margin (TTM)	-2543.7%	-553.9%
FCF Margin (TTM)	-681.2%	-322.9%
Net Income (TTM)	$-107M	$-83M
FCF (TTM)	$-29M	$-48M
EPS (TTM)	-$1.85	-$4.20
ROE (TTM)	-19474.0%	-2140.0%
ROA (TTM)	-10642.0%	-1979.0%
ROIC (TTM)	-19457.0%	-2140.0%
Financial Health
Cash	$86M	$258M
Debt	$0	$0
Net Cash/Debt	$86M	$258M
Current Ratio (TTM)	4.70x	21.96x
Quick Ratio (TTM)	4.69x	21.53x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-24.51	1.20
52W Performance	6.5%	-25.1%
YTD Performance	-37.2%	-35.5%
% from 52W High	-51.4%	-47.0%
% from 52W Low	31.8%	23.3%
Efficiency & Yields
Asset Turnover (TTM)	0.79x	0.06x
FCF Yield (TTM)	-14.7%	-20.5%
Earnings Yield (TTM)	-54.8%	-35.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-640.9	-416.5
EV/GP/RG	0.53	N/A
Ticker research	View CAMP research	View KROS research

Valuation

P/S Ratio

KROS

15.75x

CAMP

46.44x

EV/FCF

CAMP

-3.81x

KROS

0.44x

Growth & revenue

Revenue Growth TTM

CAMP

40.3%

KROS

-93.6%

Forward Revenue Growth

CAMP

-10.8%

KROS

-96.3%

Profitability & performance

Gross Margin

CAMP

35.8%

KROS

0.0%

ROE

KROS

-2140.0%

CAMP

-19474.0%

FCF Yield %

CAMP

-14.7%

KROS

-20.5%

52-Week Performance

CAMP

6.5%

KROS

-25.1%

Detailed metrics comparison

CAMP

CAMP4 Therapeutics Corp

KROS

Keros Therapeutics Inc

Market Cap

CAMP$196M

KROS$236M

Enterprise Value

CAMP$109M

KROS$-21M

Price

CAMP$3.77

KROS$11.95

P/E Ratio

CAMPN/A

KROSN/A

P/S Ratio

CAMP46.44x

KROS15.75x

EV/Sales

CAMP25.94x

KROS-1.41x

EV/EBITDA

CAMP0.00x

KROS-0.47x

P/B Ratio

CAMP8.12x

KROS0.86x

P/FCF Ratio

CAMPN/A

KROSN/A

EV/FCF

CAMP-3.81x

KROS0.44x

PEG Ratio

CAMPN/A

KROSN/A

Forward P/E (NTM)

CAMPN/A

KROSN/A

Forward P/S (NTM)

CAMP19.59x

KROSN/A

Revenue (TTM)

CAMP$4M

KROS$15M

Revenue Growth (YoY)

CAMP40.3%

KROS-93.6%

Forward Rev Growth

CAMP-10.8%

KROS-96.3%

Gross Margin (TTM)

CAMP35.8%

KROS0.0%

Operating Margin (TTM)

CAMP0.0%

KROS0.0%

EBITDA Margin (TTM)

CAMP-1199.3%

KROS-665.2%

Net Margin (TTM)

CAMP-2543.7%

KROS-553.9%

FCF Margin (TTM)

CAMP-681.2%

KROS-322.9%

Net Income (TTM)

CAMP$-107M

KROS$-83M

FCF (TTM)

CAMP$-29M

KROS$-48M

EPS (TTM)

CAMP-$1.85

KROS-$4.20

ROE (TTM)

CAMP-19474.0%

KROS-2140.0%

ROA (TTM)

CAMP-10642.0%

KROS-1979.0%

ROIC (TTM)

CAMP-19457.0%

KROS-2140.0%

Cash

CAMP$86M

KROS$258M

Debt

CAMP$0

KROS$0

Net Cash/Debt

CAMP$86M

KROS$258M

Current Ratio (TTM)

CAMP4.70x

KROS21.96x

Quick Ratio (TTM)

CAMP4.69x

KROS21.53x

Debt/Equity (TTM)

CAMP0.00x

KROS0.00x

Debt/Assets (TTM)

CAMP0.0%

KROS0.0%

Interest Coverage (TTM)

CAMPN/A

KROSN/A

Net Debt/EBITDA (TTM)

CAMP0.00x

KROS0.00x

Beta

CAMP-24.51

KROS1.20

52W Performance

CAMP6.5%

KROS-25.1%

YTD Performance

CAMP-37.2%

KROS-35.5%

% from 52W High

CAMP-51.4%

KROS-47.0%

% from 52W Low

CAMP31.8%

KROS23.3%

Asset Turnover (TTM)

CAMP0.79x

KROS0.06x

FCF Yield (TTM)

CAMP-14.7%

KROS-20.5%

Earnings Yield (TTM)

CAMP-54.8%

KROS-35.2%

Dividend Yield (TTM)

CAMPN/A

KROSN/A

Rule of 40

CAMP-640.9

KROS-416.5

EV/GP/RG

CAMP0.53

KROSN/A

Ticker research

View CAMP research View KROS research

Metric	CAMP CAMP4 Therapeutics Corp	KROS Keros Therapeutics Inc
Market & Valuation
Market Cap	$196M	$236M
Enterprise Value	$109M	$-21M
Price	$3.77	$11.95
P/E Ratio	N/A	N/A
P/S Ratio	46.44x	15.75x
EV/Sales	25.94x	-1.41x
EV/EBITDA	0.00x	-0.47x
P/B Ratio	8.12x	0.86x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.81x	0.44x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	19.59x	N/A
Revenue & Growth
Revenue (TTM)	$4M	$15M
Revenue Growth (YoY)	40.3%	-93.6%
Forward Rev Growth	-10.8%	-96.3%
Profitability
Gross Margin (TTM)	35.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1199.3%	-665.2%
Net Margin (TTM)	-2543.7%	-553.9%
FCF Margin (TTM)	-681.2%	-322.9%
Net Income (TTM)	$-107M	$-83M
FCF (TTM)	$-29M	$-48M
EPS (TTM)	-$1.85	-$4.20
ROE (TTM)	-19474.0%	-2140.0%
ROA (TTM)	-10642.0%	-1979.0%
ROIC (TTM)	-19457.0%	-2140.0%
Financial Health
Cash	$86M	$258M
Debt	$0	$0
Net Cash/Debt	$86M	$258M
Current Ratio (TTM)	4.70x	21.96x
Quick Ratio (TTM)	4.69x	21.53x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-24.51	1.20
52W Performance	6.5%	-25.1%
YTD Performance	-37.2%	-35.5%
% from 52W High	-51.4%	-47.0%
% from 52W Low	31.8%	23.3%
Efficiency & Yields
Asset Turnover (TTM)	0.79x	0.06x
FCF Yield (TTM)	-14.7%	-20.5%
Earnings Yield (TTM)	-54.8%	-35.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-640.9	-416.5
EV/GP/RG	0.53	N/A
Ticker research	View CAMP research	View KROS research